Kikuzubam (rituximab biosimilar) / Probiomed - LARVOL DELTA

Review of biologics, biosimilars, and intended copies in rheumatology, and current practice in Iraq. (PubMed, Open Access Rheumatol) - "...Thus, safety issues may arise once the product is in use, as was the case with Kikuzubam, an intended copy of rituximab that was withdrawn from the market in Mexico following reports of severe adverse reactions...In this review, we discuss issues related to the use and regulation of biosimilars, and the differences between biosimilars and intended copies. We also provide suggestions for including biosimilars as a treatment option in Iraq."

Journal • Review